Triclosan
ApprovedSmall molecule
Triclosan is one of 101 small molecule programs targeting Cardiovascular Disease. It is currently in Approved.
4
Indications
5
Total Trials
0
Active Trials
100
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
274 competitors in Cardiovascular Disease
#DrugCompanyPhaseTrials
1Triclosan
CColgate Palmolive
Approved
Cagrilintide
Novo NordiskPhase 3
Aleglitazar
RochePhase 3
Repatha
AmgenPreclinical
Farxiga
AstraZenecaPreclinical
Mounjaro
Eli LillyPreclinical
Praluent
RegeneronPreclinical
Calciferol
Alnylam PharmaceuticalsPreclinical
Myrbetriq
AstellasPreclinical
Benicar
NovartisPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Coronary Artery Bypass1 trial
Aggressive Periodontitis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Triclosan. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- CColgate Palmolive